To investigate whether MAPK inhibitors can enhance the susceptibility of thyroid tumors to CAR T-cell therapy by restoring TSHR expression.
Approach:
Study Design: Preclinical study using thyroid cancer models to assess the effects of MAPK inhibitors on TSHR expression and CAR T-cell efficacy.
Treatment Methods: Utilized MEK inhibitor trametinib and BRAF inhibitor dabrafenib to induce redifferentiation and restore TSHR expression in anaplastic thyroid cancer models.
Combination Therapy: Evaluated the effects of concurrent treatment with MAPK inhibitors and TSHR-directed CAR T cells on tumor control and survival.
Key Findings:
MAPK inhibitors increased TSHR expression in aggressive thyroid cancer models.
Concurrent treatment with MAPK inhibitors and TSHR-directed CAR T cells improved tumor control and survival compared to either treatment alone.
Antigen density influenced the response of CAR T-cell therapy, with higher TSHR expression correlating with better outcomes.
Limitations:
TSHR expression decreased rapidly after stopping MAPK inhibitors, indicating the need for further investigation into treatment timing.
The study is preclinical and requires validation in clinical trials.
